Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 15Lymphoma, Mantle-Cell 14Lymphoma, Large B-Cell, Diffuse 14Leukemia, Lymphocytic, Chronic, B-Cell 12Hodgkin Disease 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Waldenstrom Macroglobulinemia 10Lymphoma, Follicular 10Lymphoma, Non-Hodgkin 8Lymphoma, B-Cell, Marginal Zone 8Lymphoma, Large-Cell, Anaplastic 7Immunoblastic Lymphadenopathy 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, T-Cell, Cutaneous 6Burkitt Lymphoma 6Sezary Syndrome 5Recurrence 5Mycosis Fungoides 5Multiple Myeloma 5Lymphoma, Extranodal NK-T-Cell 5Lymphoma, B-Cell 4Leukemia 4Neoplasms, Plasma Cell 3Lymphoproliferative Disorders 3Lymphoma, Large-Cell, Immunoblastic 3Primary Myelofibrosis 2Lymphoma, T-Cell 2Lymphatic Diseases 2Leukemia, Myeloid, Acute 2Hematologic Neoplasms 2

Interventions

zanolimumab 2cemiplimab 1cc-486 1Sirolimus 1SUB1 protein, human 1Quality of Life 1Psychiatric Rehabilitation 1Prednisone 1Patient Reported Outcome Measures 1Observation 1Molecular Diagnostic Techniques 1Mass Screening 1Injections 1Immunotherapy 1Hematologic Tests 1Everolimus 1Drug Therapy 1Dasatinib 1Biological Therapy 1Azacitidine 14,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Skin Neoplasms × Everolimus × Lymphoid × Clear all
NCT07426484 2026-02-23

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Dana-Farber Cancer Institute

Phase 4 Not yet recruiting
80 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Waldenstrom Macroglobulinemia, Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡